De Witte Ridder schreef op 22 november 2016 08:47:
waar doen we t allemaal voor? Extract uit het prospectus:
Successful achievement of such sales development following completion of the Transaction would generate cash in-flows from product sales in 2017 of in excess of €33.0 million, which (after allowing for the additional sales costs anticipated to achieve such sales development) would render the Company
profitable at the operating result level and possibly at the net result level, depending on the sales growth actually achieved. Pharming anticipates that the Company will potentially reach profitability as much as three years earlier than under the Valeant license.
A significant portion of the efforts of the Management Board have been directed towards securing sufficient funds for the continued business of the Company and, more recently, to achieving the Transaction agreement and prepare for the financing necessary to complete it.
At present, RUCONEST® sales are growing in all markets, although such growth is relatively slow in most markets.
Pharming does not believe this is related to the product itself, which competes very effectively with all other therapies wherever a significant attempt is made to promote the product along the same lines as such competitor therapies. Instead
it seems to be directly related to low or non-existent efforts to promote the product. As the product grows even though promotion efforts are weak, then it is reasonable to assume that it will at least continue to grow at the current level if much stronger efforts are made to promote RUCONEST® in all major markets.